Search

A case report in the journal "Reactions Weekly" discusses a patient with advanced gastric cancer who developed grade 3 anaemia while receiving third-line therapy with trastuzumab deruxtecan. The patient's outcome was not specified, and details such as age, sex, route of administration, dosage, duration of treatment, and reaction onset were not provided in the report. This study highlights a potential adverse effect of trastuzumab deruxtecan in the treatment of advanced gastric cancer. [Extracted from the article]

In a case report from an open-label clinical trial, a patient with HER2-positive advanced extramammary Paget's disease developed macular oedema while receiving trastuzumab and docetaxel treatment. The patient had completed 5 cycles of treatment before experiencing grade 1 macular oedema, which led to the discontinuation of trastuzumab and docetaxel. Ultimately, the patient's macular oedema resolved after the treatment was stopped. [Extracted from the article]

A 46-year-old man experienced discomfort in the extremities and lack of efficacy while undergoing treatment with trastuzumab and docetaxel for HER2-positive salivary gland carcinoma. Despite receiving IV trastuzumab and docetaxel, he was diagnosed with leptomeningeal metastases, leading to craniospinal irradiation and intrathecal trastuzumab treatment. The discomfort in his extremities resolved after reducing the trastuzumab administration rate, but central nervous system deterioration was observed after 9 months of trastuzumab treatment. [Extracted from the article]

A study was conducted on 50 patients between August 2019 and February 2022, which included two women with HER2 positive breast cancer. Both women developed either low left ventricular ejection fraction (LVEF) or clinical cardiac dysfunction during their treatment with trastuzumab. Patient 1 experienced low LVEF, while Patient 2 developed clinical cardiac dysfunction. The specific doses, durations of treatment, and outcomes were not provided in the study. [Extracted from the article]

A retrospective observational study of 124 patients found that 19 women developed glucocorticoid-induced adrenal insufficiency (GI-AI) while taking dexamethasone as a prophylactic measure against chemotherapy side effects. These patients, who were diagnosed with breast cancer, also experienced fatigue during treatment with docetaxel. The patients received various chemotherapy regimens, including docetaxel alone or in combination with other drugs. After the cessation of dexamethasone, the patients' fatigue and GI-AI improved. [Extracted from the article]

A 42-year-old woman with serous carcinoma of the uterine cervix (SCUC) experienced an allergic reaction to carboplatin and lack of efficacy with bevacizumab treatment. She received off-label treatment with trastuzumab due to positive human epidermal growth factor receptor 2 (HER2) status. After starting trastuzumab, her symptoms improved, including resolution of pleural effusion, cough, and dyspnea. However, she did experience some side effects such as nausea, dysgeusia, peripheral sensory neuropathy, and alopecia. [Extracted from the article]

Two case reports were described in which men developed veno occlusive disease (VOD) while undergoing treatment with azathioprine or trastuzumab for gallbladder adenocarcinoma. In the first case, a 54-year-old man developed VOD during azathioprine therapy after experiencing a renal allograft rupture. In the second case, a 36-year-old man developed VOD while receiving trastuzumab for gallbladder adenocarcinoma. Both patients received supportive treatment for their condition. [Extracted from the article]

This article discusses two case reports of women in their 50s and 60s who developed drug-induced interstitial lung disease (DILD) during treatment for breast cancer. The first woman experienced a fever and chest CT showed ground-glass opacities. She was diagnosed with chemotherapy-induced DILD and treated with steroids, which resolved her symptoms. The second woman had a lack of efficacy with certain chemotherapy drugs and developed mild ground-glass opacities in her lungs. She was diagnosed with chemotherapy-induced DILD and her treatment was changed, resulting in resolution of her lung damage. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a retrospective single-arm, observational study involving 144 women conducted from 28 October 2019 to 13 October 2021, one adult woman [exact age not stated] was described, who developed neutropenia during treatment with IV trastuzumab [Kanjinti] for HER2+ breast cancer [dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A 41-year-old woman with metastatic breast cancer developed acute colitis while receiving treatment with trastuzumab. She experienced rectal bleeding three months after starting trastuzumab and underwent a colonoscopy, which revealed sigmoid diverticulosis with inflammation. The woman was ultimately diagnosed with acute colitis secondary to trastuzumab and was treated with beclometasone and mesalazine. This case highlights a potential adverse reaction to trastuzumab and the importance of monitoring patients for gastrointestinal side effects during treatment. [Extracted from the article]

This article from Reactions Weekly discusses two case studies involving patients with salivary duct carcinoma who experienced lack of efficacy during treatment with various antineoplastic drugs. The first patient, a 46-year-old man, received multiple treatments including trastuzumab and bicalutamide, but experienced disease progression. He later started trastuzumab-deruxtecan and showed partial response. The second patient, a 73-year-old woman, also had disease progression despite receiving trastuzumab-emtansine and bicalutamide. She eventually underwent resection of metastatic tumors and received trastuzumab-deruxtecan, which resulted in complete resolution of metastases. Both patients experienced side effects such as diarrhea and fatigue. [Extracted from the article]

A 26-year-old woman developed non-cirrhotic portal hypertension (NCPH) while being treated with trastuzumab-emtansine for ductal breast carcinoma. She presented with bleeding esophageal varices and elevated levels of alanine aminotransferase. Diagnostic work-up revealed NCPH, and histology showed nodular regenerative hyperplasia. The woman had previously received other treatments for her breast carcinoma and required post neoadjuvant treatment with trastuzumab-emtansine. After nine treatment cycles, she experienced hyperbilirubinemia, thrombocytopenia, elevated transaminases, and splenomegaly. The trastuzumab-emtansine treatment was discontinued, and while her transaminases returned to baseline, thrombocytopenia persisted. [Extracted from the article]

A 20-year-old woman with recurrent mucinous carcinoma of the left ovary exhibited lack of efficacy during treatment with paclitaxel, carboplatin, and trastuzumab. After undergoing fertility sparing surgery, the cancer relapsed and spread to various areas. Despite the addition of trastuzumab to her treatment, her cancer continued to progress. She then underwent debulking surgery and started second-line treatment with gemcitabine, trastuzumab, and pertuzumab, which resulted in a decrease in lung metastases and improved performance status. [Extracted from the article]

A 50-year-old woman developed cholestatic liver injury while being treated with trastuzumab for stage 4 invasive ductal breast carcinoma. She had extensive metastases to various organs and was admitted with worsening hyperbilirubinemia and transaminitis. After receiving trastuzumab infusion, her liver function worsened, and she experienced jaundice. The diagnosis of trastuzumab-associated cholestatic liver injury was made, and she was treated with ursodeoxycholic acid, which improved her condition. She did not receive trastuzumab again after this incident. [Extracted from the article]

A multicenter study observed four female patients with HER-2-positive breast cancer who experienced adverse effects while being treated with trastuzumab and pertuzumab. The patients developed decreased left ventricular ejection fraction, drug-induced liver injury, or diarrhea. The patients received either reference trastuzumab or a biosimilar version, and the adverse effects varied depending on the treatment. Treatment was temporarily stopped for the patient who developed drug-induced liver injury. [Extracted from the article]

A 60-year-old woman developed hypertension while being treated with trastuzumab for breast infiltrating ductal carcinoma. She was admitted to the emergency room after a car crash and was found to have left hemiplegia, an altered level of consciousness, and elevated blood pressure. A CT scan revealed a right intracerebral hemorrhage. The hypertension was considered to be a result of the trastuzumab treatment. The woman was treated with ACE inhibitors and calcium channel blockers and had a good recovery after 10 days. [Extracted from the article]

A 75-year-old woman developed interstitial pneumonitis while undergoing treatment for invasive ductal breast carcinoma. She received cyclical neoadjuvant chemotherapy with docetaxel, trastuzumab, and carboplatin. After the fourth cycle, she experienced symptoms such as malaise and dry cough, and a CT scan revealed lung abnormalities. She was admitted to the ICU, received antibiotics, and required mechanical ventilation. Despite treatment, her condition worsened, and she ultimately died due to interstitial pneumonitis and a large bilateral stroke. [Extracted from the article]

A 60-year-old woman developed hypertension while undergoing treatment with trastuzumab for breast infiltrating ductal carcinoma. She was admitted to the emergency room after a car crash and was found to have left hemiplegia, an altered level of consciousness, and elevated blood pressure. A CT scan revealed a right intracerebral hemorrhage. The hypertension was considered to be a result of the trastuzumab treatment. The woman was treated with ACE inhibitors and calcium channel blockers and showed good recovery after 10 days. [Extracted from the article]

A 75-year-old woman developed interstitial pneumonitis while undergoing treatment for invasive ductal breast carcinoma. She received cyclical neoadjuvant chemotherapy with docetaxel, trastuzumab, and carboplatin. After the fourth cycle, she experienced symptoms such as malaise and dry cough, and a CT scan revealed lung abnormalities. She was admitted to the ICU, received antibiotics, and required mechanical ventilation. Despite treatment, her condition worsened, and she ultimately died due to interstitial pneumonitis and a large bilateral stroke. [Extracted from the article]

A 42-year-old woman with HER2 positive breast cancer developed diarrhea while being treated with pyrotinib. She also experienced treatment failure while receiving trastuzumab. The woman had initially undergone surgery and received chemotherapy and trastuzumab. After the failure of trastuzumab, she was treated with pyrotinib and experienced diarrhea again. The development of diarrhea was attributed to pyrotinib. She continued treatment with pyrotinib and underwent brain radiotherapy. [Extracted from the article]

A systematic review and meta-analysis published in Cancer found that treatment with trastuzumab deruxtecan (DS-8201) increases the risk of interstitial lung disease (ILD) and/or pneumonitis. The study analyzed data from 13 articles involving 1428 patients with advanced solid tumors who received trastuzumab deruxtecan. The most commonly reported side effects were nausea and fatigue, while the incidence rate of ILD and/or pneumonitis was 12.5%. The authors recommend that physicians monitor and manage these adverse reactions when using trastuzumab deruxtecan. [Extracted from the article]

A 42-year-old woman with HER2 positive breast cancer developed diarrhea while being treated with pyrotinib. She also experienced treatment failure while receiving trastuzumab. The woman had initially undergone surgery and received chemotherapy and trastuzumab. After the failure of trastuzumab, she was treated with pyrotinib and experienced diarrhea again. The development of diarrhea was attributed to pyrotinib. She continued treatment with pyrotinib and underwent brain radiotherapy. [Extracted from the article]

A systematic review and meta-analysis published in Cancer found that treatment with trastuzumab deruxtecan (DS-8201) increases the risk of interstitial lung disease (ILD) and/or pneumonitis. The study analyzed data from 13 articles involving 1428 patients with advanced solid tumors who received trastuzumab deruxtecan. The most commonly reported side effects were nausea and fatigue, while the incidence rate of ILD and/or pneumonitis was 12.5%. The authors recommend that physicians monitor and manage these adverse reactions when using trastuzumab deruxtecan. [Extracted from the article]

In a real-world study of 179 patients with HER-2 positive breast cancer, two patients experienced adverse reactions while being treated with carboplatin. One patient developed severe diarrhea, while the other had high creatinine levels. Both patients had a medical history of HER-2 positive breast cancer and were receiving carboplatin in combination with other medications. The dose of carboplatin was initially reduced for both patients and eventually discontinued. [Extracted from the article]

A 51-year-old woman developed pneumonitis while undergoing treatment for stage IA invasive ductal carcinoma of the right breast with paclitaxel and trastuzumab. She experienced symptoms such as shortness of breath, cough, and chest pain, and was diagnosed with pneumonitis based on various tests. Treatment with prednisolone resulted in significant improvement, and her follow-up chest CT showed regression of the infiltrates. Her trastuzumab was discontinued, and she remained asymptomatic and stable. [Extracted from the article]

A woman in her 60s with HER2-positive invasive ductal breast cancer experienced lack of efficacy and drug intolerance during treatment with various antineoplastic drugs. She initially received chemotherapy with trastuzumab, pertuzumab, and letrozole, but her tumor markers increased and she had disease progression. She then received fulvestrant, but developed intolerance. Subsequently, she started fourth-line chemotherapy with tucatinib and trastuzumab emtansine, which led to the development of telangiectasias (red dots) on her body. She was also diagnosed with liver injury. After stopping treatment for three weeks, her telangiectasias improved, but recurred when she resumed tucatinib at a reduced dose. Electrocautery helped improve her condition, and at a three-month follow-up, her overall condition and emotional well-being had improved. [Extracted from the article]

A 48-year-old woman experienced cardiogenic shock and biventricular failure while undergoing chemotherapy with doxorubicin and trastuzumab for a tumor. Despite treatment with cardiotonics, her condition did not improve and she required extra-corporeal life support. After several days, she underwent left ventricular assist device (LVAD) and right ventricular assist device (RVAD) implantations. Analysis of myocardial tissue revealed low contractility when exposed to the chemotherapy drugs, but function recovered in the absence of the drugs. The conclusion was that the cardiogenic shock and biventricular failure were caused by the chemotherapy. [Extracted from the article]

A 75-year-old man with advanced stage IV gastric cancer exhibited lack of efficacy during treatment with capecitabine, cisplatin, and trastuzumab. He underwent laparoscopic distal gastrectomy and partial liver resection, but a 10mm recurrence of gastric carcinoma was noted 13 months post-surgery, indicating lack of efficacy to the treatment. After chemotherapy, the man underwent rehepatic resection and had no recurrence at three years of follow-up. [Extracted from the article]

A retrospective study involving 26 patients with HER2-positive metastatic breast cancer (MBC) found that some patients developed amnesia, visual deficit, dizziness, or brain edema during treatment with trastuzumab-emtansine. The patients also received intracranial radiotherapy through stereotactic radiosurgery. The study did not provide specific information about the patients' ages, sexes, treatment details, or outcomes. [Extracted from the article]

A 72-year-old woman developed a viral upper respiratory infection (URI) and Graves' disease while undergoing chemotherapy with trastuzumab. She had a history of hashimoto's thyroiditis, cerebrovascular disease, and systemic lupus erythematosus. The woman experienced hyperthyroid symptoms, including weight loss, palpitations, and hair loss, and her levothyroxine-sodium medication was discontinued. She later developed a viral URI believed to be caused by trastuzumab and received conservative management treatment. Due to elevated thyroid stimulating immunoglobulin (TSI) levels and other symptoms, her hashimoto's thyroiditis was converted to Graves' disease, and she began receiving thiamazole (methimazole) treatment. [Extracted from the article]

A 36-year-old woman developed sarcoid granulomatous lymphadenitis while undergoing treatment with trastuzumab for breast cancer. The woman had different types of breast cancer in each breast and was receiving trastuzumab along with other medications. A lymph node biopsy revealed sarcoid granulomata, but no signs of malignancy or metastases were found. The condition was determined to be related to the use of trastuzumab. [Extracted from the article]

A 45-year-old woman experienced heart failure while undergoing treatment with pertuzumab/trastuzumab for stage III HER 2-positive invasive intraductal carcinoma of the right breast. She had a history of pulmonary embolism and received 8 cycles of treatment over 11 months. Her transthoracic echocardiogram showed decreased left ventricular function and she was diagnosed with heart failure related to the medication. After discontinuing chemotherapy for 3 months and receiving medical therapy, her heart function improved and she was able to resume treatment with pertuzumab/trastuzumab. Her subsequent follow-up showed stable heart function. [Extracted from the article]

In a retrospective cohort study of patients with HER2-positive breast cancer, several individuals developed cardiotoxicity in the form of left ventricular dysfunction while being treated with trastuzumab or epirubicin. The patients experienced reduced left ventricular ejection fraction and impaired global longitudinal strain, and some also developed heart failure. Trastuzumab was continued in some cases, but three patients eventually had to discontinue the treatment due to cardiac dose-limiting toxicity. The cardiotoxicity persisted in seven patients even after completion or discontinuation of trastuzumab. The study concluded that the cardiotoxicity was related to trastuzumab and/or epirubicin. [Extracted from the article]

A 56-year-old woman developed capillary leak syndrome while receiving treatment for metastatic breast cancer with trastuzumab-deruxtecan and filgrastim. She experienced symptoms such as anasarca and significant weight gain. Despite attempts to treat her condition with diuretics, her renal function worsened. However, after receiving amiloride and tocilizumab, her condition improved, and she was discharged with marked improvement in her health. The capillary leak syndrome was believed to be a result of the medications she was taking. [Extracted from the article]

A 54-year-old man with gastric cancer and metastatic liver lesions underwent various treatments, including paclitaxel, trastuzumab, ethiodized-oil, fluorouracil, oxaliplatin, and nivolumab. However, he experienced lack of efficacy and side effects such as itching, skin redness, intermittent diarrhea, and nausea. Despite undergoing multiple procedures and receiving different medications, his condition showed progression. Ultimately, the patient underwent chemoembolization and received supportive pharmacotherapy, resulting in stabilization of the metastatic focus and a satisfactory condition. [Extracted from the article]

A 39-year-old woman with HER2-positive breast cancer and multiple brain metastases developed interstitial lung disease (ILD) while being treated with trastuzumab-deruxtecan. She also experienced a lack of efficacy with trastuzumab. After discontinuing trastuzumab-deruxtecan and receiving prednisolone, her symptoms improved. However, when she switched to trastuzumab monotherapy, radiologic progression of the brain metastases was observed. She then restarted trastuzumab-deruxtecan with prednisone and experienced improved quality of life without any recurrence of ILD. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA female patient [age not stated] developed sarcoidosis during treatment with trastuzumab for breast cancer [dosage, route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A case study involving 11 women with recurrent breast cancer found that two of them developed grade 3 neutropenia or interstitial lung disease while being treated with trastuzumab-deruxtecan, a medication for HER2-positive breast cancer. One woman experienced neutropenia but her dose was reduced after she recovered. The other woman developed interstitial lung disease and was hospitalized, but later discharged after treatment with steroids. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 45-year-old woman developed graves' disease during treatment with trastuzumab for breast cancer. The woman, who had breast cancer, received treatment with trastuzumab [Herceptin; route and dosage not stated]. However, she developed graves' disease secondary to trastuzumab [duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A study examined the cardiotoxicity of trastuzumab, a drug used to treat HER2 positive breast cancer. The study included 117 patients and found that three women experienced cardiac issues during treatment. One woman developed asymptomatic cardiotoxicity, another developed symptomatic cardiotoxicity, and a third woman experienced sudden cardiac death. The study did not provide information on the final outcomes of these adverse reactions or the duration of treatment before the onset of these reactions. [Extracted from the article]

A retrospective study involving 81 patients with HER2-positive breast cancer found that one patient developed febrile neutropenia while being treated with docetaxel, pertuzumab, and trastuzumab. The study did not provide specific details about the patient's age, sex, treatment regimen, or outcome. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 52-year-old man exhibited lack of efficacy during treatment with gemcitabine, paclitaxel, demcizumab, entrectinib, brigatinib, lorlatinib, capecitabine, oxaliplatin, pembrolizumab, trastuzumab, pemetrexed, pertuzumab, bevacizumab, docetaxel, osimertinib and trastuzumab-deruxtecan for metastatic pancreatic cancer [dosages and routes not stated]. [Extracted from the article]

A retrospective study conducted between 2019 and 2022 examined the efficacy of tucatinib, trastuzumab, and capecitabine in treating HER2 positive advanced metastatic breast cancer. The study involved 31 patients, one of whom exhibited a lack of efficacy during treatment with these drugs. The patient had previously received these therapies but experienced disease progression. The patient was then switched to trastuzumab-deruxtecan, which resulted in stable condition for their advanced metastatic breast cancer. [Extracted from the article]

A 61-year-old man with gastro-oesophageal junction adenocarcinoma and multiple liver metastases experienced intolerance and neuropathy while being treated with capecitabine and oxaliplatin. He also exhibited lack of efficacy with trastuzumab, nivolumab, ramucirumab, paclitaxel, and unspecified immunotherapies. Despite various treatment modifications, including changes in medication and immunotherapies, the patient experienced disease progression multiple times. Supportive care was initiated, but the patient ultimately died from gastro-oesophageal junction adenocarcinoma. [Extracted from the article]

A 44-year-old woman with metastatic human epidermal growth factor receptor 2 (HER2) positive grade III invasive breast cancer exhibited lack of efficacy during treatment with multiple drugs, including carboplatin, catequentinib, cyclophosphamide, doxorubicin-liposomal, paclitaxel, pertuzumab, pyrotinib, trastuzumab, trastuzumab-emtansine, and vinorelbine. Despite undergoing various treatments, her MRI showed progressive enlargement of breast lesions and axillary nodes, indicating lack of efficacy. However, after receiving IV disitamab-vedotin and IV zimberelimab, her tumor lesions significantly shrunk and eventually disappeared, and she remained in remission as of March 2023. [Extracted from the article]

This article discusses six case reports of patients who experienced various dermatological toxicities while undergoing treatment with monoclonal antibodies for different types of cancer. The patients developed symptoms such as rash, itchy rash, maculopapular rash, peau d'orange hyperpigmentation, groin rash, retracted nipple, and skin hyperpigmentation. The toxicities were attributed to the specific monoclonal antibody treatments they were receiving, including cetuximab, panitumumab, pembrolizumab, pertuzumab, and trastuzumab. The patients' ages ranged from 39 to 62 years, and they were being treated for sigmoid cancer, rectal cancer, lung cancer, or breast cancer. [Extracted from the article]

A retrospective study involving 175 breast cancer patients found that a woman developed nonsustained ventricular tachycardia (NSVT), premature ventricular contractions (PVC), and cardiotoxicity while being treated with trastuzumab. The woman had previously received anthracycline therapy and had HER2 positive invasive ductal carcinoma of the breast. The left ventricular ejection fraction was ≤50%. The specific details of the woman's treatment, including dosage and duration, as well as the outcome, were not provided in the study. [Extracted from the article]

A 50-year-old man with pancreatic adenocarcinoma underwent multiple treatments including chemotherapy, chemoradiation, surgery, and targeted therapies. Despite initial response and tumor regression, the patient experienced lack of efficacy to various drugs including fluorouracil, gemcitabine, paclitaxel, trastuzumab, and pembrolizumab. The disease progressed, and the patient developed metastatic lung lesions and respiratory complications. Despite extensive treatment, the patient's condition deteriorated, and he ultimately passed away. A post-mortem analysis of the lung tumor provided insights into tumor heterogeneity over the course of five years. [Extracted from the article]

This article discusses four case reports of patients with gastric adenocarcinoma who experienced various toxicities and lack of efficacy while receiving immunotherapies. The patients, aged between 67 and 76 years, developed symptoms such as fever, immune-related myocarditis, shivering, urinary retention, and erythra during treatment with nivolumab, ipilimumab, trastuzumab, or sintilimab. One patient also showed lack of efficacy despite receiving sintilimab and ipilimumab. All four patients underwent surgery after experiencing these complications. It is important for researchers and medical professionals to be aware of these potential side effects when considering immunotherapy for gastric adenocarcinoma. [Extracted from the article]

A woman in her 50's experienced nausea while being treated with trastuzumab deruxtecan for HER2-amplified non-small-cell lung cancer (NSCLC). She also showed lack of efficacy when treated with carboplatin, pemetrexed, and pembrolizumab for the same condition. The woman had a history of breast cancer and had undergone mastectomy and lobectomy in the past. Despite experiencing side effects, her nausea improved when the dosage of trastuzumab deruxtecan was reduced, and she achieved a partial response in her NSCLC. [Extracted from the article]